KEYTRUDA® (pembrolizumab) - Official Site
WEBKEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy medicines carboplatin and paclitaxel, and then KEYTRUDA may be used alone, in adults: when your cancer has spread (advanced), or; if your cancer has returned. KEYTRUDA may be used alone in ...
Pembrolizumab - Wikipedia
WEBPembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Keytruda Logo & Brand Assets (SVG, PNG and vector) - Brandfetch
WEBFind the Keytruda style guide with brand assets such as logos, colors, fonts, and more.
Keytruda Images - What does Keytruda look like? - Drugs.com
WEBView images of Keytruda and identify pills by imprint code, shape and color with the Drugs.com Pill Identifier.
Frequently Asked Questions About Keytruda® (pembrolizumab)
WEBDec 19, 2018 · What is the mechanism of action Keytruda? Keytruda is anti-PD-1 antibody. It blocks PD-1, a protein that interferes with certain types of immune responses and may enhance the ability of the immune system to fight cancer. How is Keytruda typically given (administered)? Keytruda is given by intravenous infusion, usually once every three weeks.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult …
WEBMay 25, 2017 · KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
pembrolizumab (KEYTRUDA) | FDA - U.S. Food and Drug …
WEBOn August 5, 2016, the U. S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp.) for the treatment of patients with...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEBOct 13, 2021 · KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
KEYTRUDA® (pembrolizumab) for Non–Small Cell Lung Cancer
WEBKEYTRUDA may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamous” and your tumor does not have an abnormal “EGFR” or “ALK” gene.
Keytruda | European Medicines Agency (EMA)
WEBJul 30, 2015 · Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD L1 with a CPS ≥ 1.
- Some results have been removed